Compositions and methods for inhibiting expression of GSK-3 genes

1. A double-stranded ribonucleic acid (dsRNA), comprising a sense strand and an antisense strand, each strand between 15 and 30 nucleotides in length and the dsRNA comprising a duplex structure between 15 and 30 basepairs in length and the sense strand comprising a first sequence and the antisense strand comprising a second sequence, the second sequence comprising a region complementary to at least 16 contiguous nucleotides of SEQ ID NO:13096.

2. The dsRNA of claim 1 , wherein the sense strand comprises SEQ ID NO:13096 and the antisense strand comprises SEQ ID NO:13107.

3. The dsRNA of claim 1 , wherein the sense strand consists of SEQ ID NO:13096 and the antisense strand consists of SEQ ID NO:13107 and each strand includes an overhang of 0, 1, or 2 nucleotides.

4. The dsRNA of claim 1 , wherein said dsRNA comprises at least one modified nucleotide.

5. The dsRNA of claim 4 , wherein said modified nucleotide is chosen from the group of: a 2′-O-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group, a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide.

6. The dsRNA of claim 4 , comprising at least one 2′-O-methyl modified nucleotide and at least one nucleotide comprising a 5′-phosphorothioate group.

7. The dsRNA of claim 1 , wherein the region of complementarity is between 19 and 21 nucleotides in length.

8. The dsRNA of claim 1 , wherein the region of complementarity is 19 nucleotides in length.

9. The dsRNA of claim 1 , wherein administration of the dsRNA inhibits expression of GSK3 by more than 40%.

10. The dsRNA of claim 1 , wherein the dsRNA exhibits an IC50 of less than or equal to 10 nM in suppressing GSK3.

11. The dsRNA of claim 1 , wherein the dsRNA exhibits an IC50 of less than or equal to 1.0 nM in suppressing GSK3.

12. A cell comprising the dsRNA of claim 1 .

13. A vector comprising at least one strand of the dsRNA of claim 1 .

14. A cell comprising the vector of claim 13 .

15. A pharmaceutical composition for inhibiting expression of an GSK-3 gene comprising the dsRNA of claim 1 .

16. A method of inhibiting GSK-3 expression in a cell, the method comprising:

(a) introducing into the cell the dsRNA of claim 1 ; and

(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of a GSK-3 gene, thereby inhibiting expression of a GSK-3 gene in the cell.

17. The dsRNA of claim 1 , the second sequence comprising a region complementary to at least 17 contiguous nucleotides of SEQ ID NO:13096.

18. The dsRNA of claim 1 , the second sequence comprising a region complementary to at least 18 contiguous nucleotides of SEQ ID NO:13096.

19. The dsRNA of claim 1 , the second sequence comprising a region complementary to 19 contiguous nucleotides of SEQ ID NO:13096.

20. The dsRNA of claim 2 or 3 , wherein said dsRNA comprises at least one modified nucleotide.

21. The dsRNA of claim 2 or 3 , wherein said dsRNA comprises at least one 2′-O-methyl modified nucleotide and at least one nucleotide comprising a 5′-phosphorothioate group.

22. A pharmaceutical composition for inhibiting expression of an GSK-3 gene comprising the dsRNA of claim 2 or 3 .

23. A method of inhibiting GSK-3 expression in a cell, the method comprising:

(a) introducing into the cell the dsRNA of claim 2 or 3 ; and

(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of a GSK-3 gene, thereby inhibiting expression of a GSK-3 gene in the cell.